Values First Advisors’s Freeline Therapeutics Holdings plc American Depositary Shares FRLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-3,753
Closed -$49K 163
2022
Q2
$49K Buy
3,753
+410
+12% +$5.27K 0.03% 150
2022
Q1
$56K Buy
3,343
+1,806
+118% +$33.5K 0.04% 157
2021
Q4
$46K Buy
1,537
+142
+10% +$5.8K 0.03% 165
2021
Q3
$71K Buy
+1,395
New +$99.2K 0.05% 141

Other funds holding FRLN

Values First Advisors's FRLN Position: Q3 2022 in Review

Values First Advisors sold out of Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) in Q3 2022, closing a stake of 3,753 shares — an estimated $49K sold.

Values First Advisors first reported a position in FRLN in Q3 2021 and held it in 4 quarters. The position peaked at $71K in Q3 2021. 14 funds tracked by Wall St. Rank hold FRLN as of Q3 2022.

  • Values First Advisors reported no remaining Freeline Therapeutics Holdings plc American Depositary Shares position as of Q3 2022 after selling out during the quarter.
  • Values First Advisors sold 3,753 Freeline Therapeutics Holdings plc American Depositary Shares shares in Q3 2022, an estimated $49K.
  • Values First Advisors first reported a position in Freeline Therapeutics Holdings plc American Depositary Shares in Q3 2021 and held it in 4 quarters.
  • Values First Advisors's Freeline Therapeutics Holdings plc American Depositary Shares position peaked at $71K in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings plc American Depositary Shares as of Q3 2022.

Based on Values First Advisors's 13F filing for Q3 2022, filed 2 Dec 2022.